A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
- Conditions
- Hypoplasminogenemia
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Registration Number
- NCT03642691
- Locations
- ๐บ๐ธ
Tower Hematology and Oncology, Beverly Hills, California, United States
๐บ๐ธIndiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
๐บ๐ธVanderbilt University Medical Center, Nashville, Tennessee, United States
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
- Conditions
- Hypoplasminogenemia
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Registration Number
- NCT03265171
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
Phase 2
Completed
- Conditions
- HypoplasminogenemiaCongenital Plasminogen Deficiency
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02690714
- Locations
- ๐บ๐ธ
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
๐ณ๐ดOslo University Hospital HF, Oslo, Sognsvannvejen 20, Norway
A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
Phase 1
Completed
- Conditions
- Type I Plasminogen DeficiencyHypoplasminogenemia
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02312180
- Locations
- ๐บ๐ธ
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Phase 3
Completed
- Conditions
- Primary Immunodeficiency
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Prometic Biotherapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02269163
- Locations
- ๐บ๐ธ
University of California, Irvine, Irvine, California, United States
๐บ๐ธChildren's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธImmunoe International Research, Centennial, Colorado, United States